Physician profile
Hatira Watts
NPI 1598130361
$2,013.81
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,080 · 2023: $103 · 2024: $831.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $933.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $933.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $426.46 | 2021-2024 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Teva Pharmaceuticals USA, INC. | $269.50 | 2021-2024 | Austedo Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $239.90 | 2021-2024 | Caplyta |
| Eisai INC. | $169.96 | 2021 | |
| Abbvie INC. | $152.84 | 2021-2024 | |
| E.R. Squibb & Sons, L.L.C. | $121.04 | 2024 | Cobenfy |
| Alkermes, INC. | $117.30 | 2024 | Lybalvi |
| Lundbeck LLC | $93.89 | 2021 | |
| Validus Pharmaceuticals LLC | $88.86 | 2021 | |
| Sunovion Pharmaceuticals INC. | $81.78 | 2021 | |
| Vanda Pharmaceuticals INC. | $77.04 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $74.74 | 2021 | |
| Brainsway USA INC | $35.97 | 2024 | Brainsway Deep Tms System |
| Ironshore Pharmaceuticals INC. | $22.01 | 2021 | |
| Bausch Health US, LLC | $16.76 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $14.33 | 2021 | |
| Indivior INC. | $11.43 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hatira Watts listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.